Two Indian vaccinemakers are ramping up production of their swine flu vaccines, to replace stocks that were destroyed recently after they expired.
Swine flu is making a comeback in India, and with a vengeance. After destroying their existing stocks due to poor demand and short shelf life, Serum Institute and Bharat Biotech will be racing to get their swine flu vaccines back on the market.
Researchers at Kansas State University were recently given a $1.1 million grant from the U.S. National Institutes of Health to study swine flu.
While Finland agreed to pay out in 2011, the U.K. was still knocking back claimants in 2012. Now, though, the U.K. government is reportedly readying to pay 60 people $1.7 million each.
Blogs and social media chatter often paint liberals, particularly Whole Foods-shopping, "earth mother" types, as the lead proponents of the anti-vaccine movement. Yet this view has been contradicted by surveys in the past, and was once again revealed to be flawed by data published this week.
Human immune systems were ill-prepared for the swine flu virus that spread across the globe in 2009. The lack of pre-existing immunity left people vulnerable but, researchers wondered, was everyone equally unprotected? Answering this question has led to a 'blueprint' for a universal flu vaccine.
Evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy has mounted up this year, with new findings from Finland, Sweden and the United Kingdom emerging. Now, having previously knocked back compensation claims, the data has prompted the U.K. government to accept the link.
From 2009 to 2011, 25 adults developed narcolepsy in Finland, 18 of whom had received GSK's swine flu vaccine, Pandemrix.
The Swedish regulator has added to evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy in a registry study of 5.8 million people.
Research linking GlaxoSmithKline's ($GSK) swine flu vaccine to narcolepsy has precipitated calls for a rereview of a similar product before FDA makes an approval decision.